Core Insights - Palisade Bio is focusing on developing PALI-2108 as a potential leader in treating Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD) due to the significant unmet need for more effective treatment options [1][3] Company Overview - Palisade Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases [2][5] - The company aims to transform the treatment landscape through a targeted approach with its innovative therapeutics [5] Expert Insight - Dr. Brian Feagan, a leading expert in IBD and FSCD, discussed the challenges of current therapies and emphasized the need for treatments that effectively address both inflammation and fibrosis [3] - He highlighted PALI-2108's localized approach, which aims to minimize class-associated side effects while maintaining anti-inflammatory and anti-fibrotic efficacy [3]

Core Insights - Palisade Bio, Inc. has appointed Emil Chuang, MB BS FRACP to its Board of Directors, enhancing its clinical strategy in treating Fibrostenotic Crohn's Disease and Ulcerative Colitis [1][9] Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases [10] Leadership Experience - Dr. Chuang brings nearly 25 years of pharmaceutical and clinical experience, including contributions to drug development programs that led to two successful regulatory approvals: infliximab for pediatric Crohn's disease and lorcaserin for morbid obesity [3][4] - His previous roles include Chief Medical Officer at Intrinsic Medicine and leadership positions at Nestlé Health Science, Takeda, and Progenity, with over 80 peer-reviewed publications to his name [6][7] Strategic Importance - The addition of Dr. Chuang is expected to provide valuable insights into the company's clinical programs, particularly in inflammatory bowel diseases [5][6] - The company aims to leverage Dr. Chuang's expertise to advance its pipeline and address unmet medical needs in the therapeutic landscape [6]

Core Insights - Palisade Bio, Inc. presented positive preclinical data for PALI-2108, a colon-specific PDE4 inhibitor prodrug aimed at treating ulcerative colitis, demonstrating its efficacy in modulating inflammatory pathways and promoting a favorable immune response [1][3][6] - The company is advancing a Phase 1a/b study of PALI-2108, which has shown a favorable safety profile in single-ascending-dose cohorts [1][3] Preclinical Study Findings - PALI-2108 was tested in a mouse model of colitis, showing significant improvements in clinical parameters such as Disease Activity Index (DAI), body weight, and colon length in a dose-dependent manner [6] - The treatment resulted in a marked reduction of PDE4B expression in colon tissues, increased cAMP levels, and notable suppression of TNF-α compared to standard treatments like cyclosporine A and apremilast [6] - The study utilized 4% dextran sulfate sodium (DSS) to induce colitis in mice, with various dosages of PALI-2108 administered [3][6] Pharmacokinetics and Safety - Pharmacokinetic modeling indicated that PALI-2108 has favorable absorption and bioavailability, supporting its potential for clinical use [4] - The preclinical data highlighted minimal CNS toxicity and favorable dose-dependent effects, reinforcing the drug's safety profile [6] Presentation and Recognition - The first poster on PALI-2108 was recognized as a Poster of Distinction at Digestive Disease Week 2025, showcasing its significance in the field of gastrointestinal disorders [2][5] Ongoing Clinical Studies - The company is conducting a Phase 1a/b single-center, double-blind, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers [7]